⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4556181 | 1.00 | GPR119 (0.43) | — | |
| SCHEMBL7928 | 1.00 | — | — | |
| Methane SCHEMBL2671466 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL6489107 | 0.97 | — | — | |
| Iodide SCHEMBL28520797 | 0.97 | GPR119 (0.42) | — | |
| Ethane SCHEMBL27516222 | 0.97 | GPR119 (0.42) | — | |
| Hno SCHEMBL27257994 | 0.91 | GPR119 (0.39) | — | |
| SCHEMBL23107536 | 0.89 | — | — | |
| SCHEMBL19045196 | 0.89 | — | — | |
| SCHEMBL2487331 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149648-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 2009-06-11 | — | — | US | claimed |
| US-7439350-B2 | Nucleotide analogs | GILEAD SCIENCES, INC. (US) | 2008-10-21 | — | — | US | claimed |
| US-6225460-B1 | PHOSPHOAMIDATE OR ESTER BOND THAT IS HYDROLYZED IN VIVO TO YIELD A CORRESPONDING PHOSPHONATE NUCLEOTIDE ANALOG. | GILEAD SCIENCES, INC. | 2001-05-01 | — | — | US | claimed |
| US-5656745-A | AMIDATE LINKAGE; ANTITUMOR, ANTICARCINOGENIC AGENTS | GILEAD SCIENCES, INC. (US) | 1997-08-12 | — | — | US | claimed |
| EP-0719273-B1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES INC (US) | 2010-11-03 | — | — | EP | disclosed |
| US-20090149648-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-7439350-B2 | Nucleotide analogs | GILEAD SCIENCES, INC. (US) | 2008-10-21 | — | — | US | disclosed |
| EP-1396491-A2 | 2-substituted 4,5-diaryl-imidazoles and their use as p38 MAP kinase inhibitors | Novartis AG (CH) | 2004-03-10 | — | — | EP | disclosed |
| US-6300347-B1 | FOR THERAPY OF TUMOR NECROSIS FACTOR AND INTERLEUKIN-1 MEDIATED DISEASES SUCH AS RHEUMATOID ARTHRITIS AND DISEASES OF BONE METABOLISM, E.G. OSTEOPOROSIS | NOVARTIS AG (CH) | 2001-10-09 | — | — | US | disclosed |
| US-6225460-B1 | PHOSPHOAMIDATE OR ESTER BOND THAT IS HYDROLYZED IN VIVO TO YIELD A CORRESPONDING PHOSPHONATE NUCLEOTIDE ANALOG. | GILEAD SCIENCES, INC. | 2001-05-01 | — | — | US | disclosed |
| EP-0993456-A1 | 2-SUBSTITUTED 4,5-DIARYL IMIDAZOLES | Novartis AG (CH) | 2000-04-19 | — | — | EP | disclosed |
| WO-1999001449-A1 | 2-SUBSTITUTED 4,5-DIARYL IMIDAZOLES | NOVARTIS AG (CH) | 1999-01-14 | — | — | WO | disclosed |
| US-5798340-A | ANTITUMOR/ANTINEOPLASTIC ACTIITY, VIRICIDES; BROAD SPECTRUM MICROBIOCIDES; THIOPHOSPHONATES HYDROLYZABLE IN VIVO; ORAL ADMINISTRATION; BIOAVAILABILITY; NONTOXIC; POTENCY | GILEAD SCIENCES, INC. (US) | 1998-08-25 | — | — | US | disclosed |
| EP-0719273-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| WO-1995007920-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |